The effects of bisphosphonates on inflammatory markers and atherosclerosis

Canan Akkuş

Makale detayları

The effects of bisphosphonates on inflammatory markers and atherosclerosis

Yazarlar:

Canan Akkuş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.447-450

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355598

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: Atherosclerosis and osteoporosis are prevalent conditions associated with significant morbidity and mortality worldwide. Evidence of literature suggests that bisphosphonates BP may play a role in inhibiting atherogenesis. The pathophysiological mechanisms underlying both atherosclerosis and osteoporosis share similarities, and numerous studies have shown an association between osteoporosis and cardiovascular events. This study aims to evaluate the effects of oral BP therapy on vascular inflammatory markers and carotid intima-media thickness CIMT, a surrogate marker of atherosclerosis, in osteoporotic patients. Methods: The study included 28 osteoporotic patients study group and 28 osteopenic patients control group. BP therapy alendronate 70 mgweek, risedronate 35 mgweek was administered to the study group in a randomized controlled way. The patients of the both groups received daily supplements of calcium 1000 mg and vitamin D 880 IU. Baseline and 12-month follow-up measurements included height, weight, body-mass index BMI, high-sensitivity C-reactive protein hs-CRP, homocysteine levels, CIMT, and bone mineral density BMD. Results: At the 12-month follow-up, hs-CRP levels decreased significantly in the study group, while they increased slightly in the control group p0.032. Similarly, homocysteine levels showed a significant reduction in the study group compared to the control group p0.002. No significant change in CIMT was observed between the two groups over the study period. Conclusion: Our findings suggest that while oral BPs may influence certain vascular inflammatory markers, such as hs-CRP and homocysteine but they do not have a significant effect on CIMT. BPs may exert anti-atherosclerotic effects through the mevalonate pathway, but the results of this study warrant further investigation with larger sample sizes to confirm the broader implications of BPs in atherosclerosis management.

 Aims: Atherosclerosis and osteoporosis are prevalent conditions associated with significant morbidity and mortality worldwide. Evidence of literature suggests that bisphosphonates BP may play a role in inhibiting atherogenesis. The pathophysiological mechanisms underlying both atherosclerosis and osteoporosis share similarities, and numerous studies have shown an association between osteoporosis and cardiovascular events. This study aims to evaluate the effects of oral BP therapy on vascular inflammatory markers and carotid intima-media thickness CIMT, a surrogate marker of atherosclerosis, in osteoporotic patients. Methods: The study included 28 osteoporotic patients study group and 28 osteopenic patients control group. BP therapy alendronate 70 mgweek, risedronate 35 mgweek was administered to the study group in a randomized controlled way. The patients of the both groups received daily supplements of calcium 1000 mg and vitamin D 880 IU. Baseline and 12-month follow-up measurements included height, weight, body-mass index BMI, high-sensitivity C-reactive protein hs-CRP, homocysteine levels, CIMT, and bone mineral density BMD. Results: At the 12-month follow-up, hs-CRP levels decreased significantly in the study group, while they increased slightly in the control group p0.032. Similarly, homocysteine levels showed a significant reduction in the study group compared to the control group p0.002. No significant change in CIMT was observed between the two groups over the study period. Conclusion: Our findings suggest that while oral BPs may influence certain vascular inflammatory markers, such as hs-CRP and homocysteine but they do not have a significant effect on CIMT. BPs may exert anti-atherosclerotic effects through the mevalonate pathway, but the results of this study warrant further investigation with larger sample sizes to confirm the broader implications of BPs in atherosclerosis management.

 Aims: Atherosclerosis and osteoporosis are prevalent conditions associated with significant morbidity and mortality worldwide. Evidence of literature suggests that bisphosphonates BP may play a role in inhibiting atherogenesis. The pathophysiological mechanisms underlying both atherosclerosis and osteoporosis share similarities, and numerous studies have shown an association between osteoporosis and cardiovascular events. This study aims to evaluate the effects of oral BP therapy on vascular inflammatory markers and carotid intima-media thickness CIMT, a surrogate marker of atherosclerosis, in osteoporotic patients. Methods: The study included 28 osteoporotic patients study group and 28 osteopenic patients control group. BP therapy alendronate 70 mgweek, risedronate 35 mgweek was administered to the study group in a randomized controlled way. The patients of the both groups received daily supplements of calcium 1000 mg and vitamin D 880 IU. Baseline and 12-month follow-up measurements included height, weight, body-mass index BMI, high-sensitivity C-reactive protein hs-CRP, homocysteine levels, CIMT, and bone mineral density BMD. Results: At the 12-month follow-up, hs-CRP levels decreased significantly in the study group, while they increased slightly in the control group p0.032. Similarly, homocysteine levels showed a significant reduction in the study group compared to the control group p0.002. No significant change in CIMT was observed between the two groups over the study period. Conclusion: Our findings suggest that while oral BPs may influence certain vascular inflammatory markers, such as hs-CRP and homocysteine but they do not have a significant effect on CIMT. BPs may exert anti-atherosclerotic effects through the mevalonate pathway, but the results of this study warrant further investigation with larger sample sizes to confirm the broader implications of BPs in atherosclerosis management.

 Aims: Atherosclerosis and osteoporosis are prevalent conditions associated with significant morbidity and mortality worldwide. Evidence of literature suggests that bisphosphonates BP may play a role in inhibiting atherogenesis. The pathophysiological mechanisms underlying both atherosclerosis and osteoporosis share similarities, and numerous studies have shown an association between osteoporosis and cardiovascular events. This study aims to evaluate the effects of oral BP therapy on vascular inflammatory markers and carotid intima-media thickness CIMT, a surrogate marker of atherosclerosis, in osteoporotic patients. Methods: The study included 28 osteoporotic patients study group and 28 osteopenic patients control group. BP therapy alendronate 70 mgweek, risedronate 35 mgweek was administered to the study group in a randomized controlled way. The patients of the both groups received daily supplements of calcium 1000 mg and vitamin D 880 IU. Baseline and 12-month follow-up measurements included height, weight, body-mass index BMI, high-sensitivity C-reactive protein hs-CRP, homocysteine levels, CIMT, and bone mineral density BMD. Results: At the 12-month follow-up, hs-CRP levels decreased significantly in the study group, while they increased slightly in the control group p0.032. Similarly, homocysteine levels showed a significant reduction in the study group compared to the control group p0.002. No significant change in CIMT was observed between the two groups over the study period. Conclusion: Our findings suggest that while oral BPs may influence certain vascular inflammatory markers, such as hs-CRP and homocysteine but they do not have a significant effect on CIMT. BPs may exert anti-atherosclerotic effects through the mevalonate pathway, but the results of this study warrant further investigation with larger sample sizes to confirm the broader implications of BPs in atherosclerosis management.

Makale detayları

The effects of bisphosphonates on inflammatory markers and atherosclerosis

Yazarlar:

Canan Akkuş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.447-450

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355598

pISSN:

2718-0115

Atherosclerosis

bisphosphonates

vascular inflammatory markersAtherosclerosis

bisphosphonates

vascular inflammatory markers

Sayı

Makale detayları

The effects of bisphosphonates on inflammatory markers and atherosclerosis

Yazarlar: Canan Akkuş

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: İç Hastalıkları

Dergi: Anatolian Current Medical Journal Vol.7 Issue 4, pp.447-450

Belge Tipi: Makale

Yayın Tarihi: 7/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001355598

pISSN: 2718-0115

Atherosclerosis

bisphosphonates

vascular inflammatory markersAtherosclerosis

bisphosphonates

vascular inflammatory markers

Sayı

Yazarlar:

Canan Akkuş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.447-450

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355598

pISSN:

2718-0115